Allogene Therapeutics ALLO Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

PrecigenPGEN

——

Immix Biopharma, Inc.IMMX

——

Artiva Biotherapeutics, Inc.ARTV

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's cash cash equivalents and short term investments?: Allogene Therapeutics (ALLO) reported cash cash equivalents and short term investments of $266.9M in Q1 2026.
How has Allogene Therapeutics's cash cash equivalents and short term investments changed year-over-year?: Allogene Therapeutics's cash cash equivalents and short term investments decreased by 20.4% year-over-year, from $335.5M to $266.9M.